Valganciclovir: Oral prevention and treatment of cytomegalovirus in the immunocompromised host

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 2007-2016

  Freeman, Richard B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

AIDS retinitis; Antiviral agents; CMV prophylaxis; Cytomegalovirus; Ganciclovir; Herpes viruses; Solid organ transplantation; Valganciclovir

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; GANCICLOVIR DERIVATIVE; PROTEIN KINASE; VALGANCICLOVIR;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARCINOGENICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FEVER; GENE MUTATION; GONAD DYSFUNCTION; GRAFT REJECTION; HEADACHE; HEART TRANSPLANTATION; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; IMMUNE DEFICIENCY; INSOMNIA; KIDNEY TRANSPLANTATION; LEUKOCYTOSIS; LEUKOPENIA; LIVER TRANSPLANTATION; LYMPHADENOPATHY; MEDICAL DECISION MAKING; MUTAGENICITY; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PNEUMONIA; RETINA DETACHMENT; RETINITIS; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VIRUS INHIBITION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; GANCICLOVIR; HUMANS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

EID: 4544336451     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.2007     Document Type: Article

References (53)

1. KRECH U: Complement-fixation antibodies against cytomegalovirus in different parts of the world. Bull. World Health Organ. (1973) 49:103.
2. HORWITZ CA, HENLE W, HENLE G et al.: Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Balt.) (1986) 65:124.
3. BOPPANA SB, RIVERA LB, FOWLER KB, MACH M, BRITT WJ: Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. (2001) 344(18):1366-1371.
4. JORDAN MC, ROUSSEAU WE, NOBLE GR et al.: Association of cervical cytomegaloviruses with venereal disease. N. Engl. J. Med. (1973) 288:932.
5. PASS RF, LITTLE EA, STAGNO S, BRITT WJ, ALFORD CA: Young children as a probable source of maternal and congenital cytomegalovirus infection. N. Engl. J. Med. (1987) 316(22):1366-1370.
6. ADLER SP: Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day care center, their parents, and caretakers. J. Pediatr. (1988) 112(3):366-372.
7. BLACKMAN JA, MURPH JR, BALE JF Jr: Risk of cytomegalovirus infection among educators and health care personnel serving disabled children. Pediatr. Infect. Dis. J. (1987) 6(8):725-729.
8. TOLPIN MD, STEWARD JA, WARREN D et al.: Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J. Pediatr. (1985) 107:953.
9. RUBIN RH: Infectious disease complications of renal transplantation. Kidney Int. (1993) 44:221.
10. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N. Engl. J. Med. (1992) 326:213.
11. PARADIS IL, WILLIAMS P: Infection after lung transplantation. Semin. Respir. Infect. (1993) 8(3):207-215.
12. CLARKE J, CRAIG RM, SAFFRO R, MURPHY P, YOKOO H: Cytomegalovirus granulomatous hepatitis. Am. J. Med. (1979) 66(2):264-269.
13. BROWNE G, WHITWORTH C, BELLAMY C, OGILVIE MM: Acute allograft glomerulopathy associated with CMV viraemia. Nephrol. Dial. Transplant. (2001) 16(4):861-862.
14. GOODGAME RW: Gastrointestinal cytomegalovirus disease. Ann. Intern. Med. (1993) 119(9):924-935.
15. COHEN JI, COREY GR: Cytomegalovirus infection in the normal host. Medicine (1985) 64(2):100-114.
16. PHILLIPS CA, FANNING WL, GUMP DW, PHILLIPS CF: Cytomegalovirus encephalitis in immunologically normal adults. Successful treatment with vidarabine. JAMA (1977) 238(21):2299-2300.
17. HIGH KP: Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence. Clin. Infect. Dis. (1999) 28(4):746-749.
18. SAGEDA S, NORDAL KP, HARTMANN A et al.: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant. (2002) 2(9):850-856.
19. HELANTERA I, KOSKINEN P, TORNROTH T, LOGINOV R, GRONHAGEN-RISKA C, LAUTENSCHLAGER I: The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation (2003) 75(11):1858-1864.
20. LAUTENSCHLAGER I, HOCKERSTEDT K, JALANKO H et al.: Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology (1997) 25(1):190-194.
21. FALAGAS ME, SNYDMAN DR, GRIFFITH J, RUTHAZER R, WERNER BG, and the BOSTON CENTER FOR LIVER TRANSPLANTATION CMVIG STUDY GROUP: Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann. Intern. Med. (1997) 126:275-279.
22. PAAVONEN T, MENNANDER A, LAUTENSCHLAGER I, MATTILA S, HAYRY P: Endothelialitis and accelerated arteriosclerosis in human heart transplant coronaries. J. Heart Lung Transplant. (1993) 12(1 Part 1):117-122.
23. ROSEN HR, CHOU S, CORLESS CL et al.: Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation (1997) 64(5):721-726.
24. RAZONABLE RR, BURAK KW, VAN CRUIJSEN H et al.: The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin. Infect. Dis. (2002) 35(8):974-981.
25. BUHLES WC et al.: Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev. Infect. Dis. (1988) 10:S495.
26. FRANK I, FRIEDMAN HM: Progress in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. (1988) 109(10):769-771.
27. ERICE A, JORDAN MC, CHACE BA, FLETCHER C, CHINNOCK BJ, BALFOUR HH Jr: Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA (1987) 257:3082-3087.
28. JACOBSON MA: Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. (1997) 337:105.
29. SCHMIDT GM, HORAK DA, NILAND JC, DUNCAN SR, FORMAN SJ, ZAIA JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N. Engl. J. Med. (1991) 324(15):1005-1011.
30. ATKINSON K, DOWNS K, GOLENIA M et al.: Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br. J. Haematol. (1991) 79(1):57-62.
31. FISHMAN JA, RUBIN RH: Infection in organ-transplant recipients. N. Engl. J. Med. (1998) 338:1741.
32. WHITLEY RJ, JACOBSON MA, FRIEDBERG DN et al.: Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy-recommendations of an international panel. International AIDS Society-USA Arch. Intern. Med. (1998) 158(9):957-969.
33. BRENNAN DC, GARLOCK KA, SINGER GG et al.: Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation (1997) 64(12):1843-1846.
34. PATEL R, SNYDMAN DR, RUBIN RH et al.: Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation (1996) 61:1279.
35. GANE E, SALIBA F, VALDECASAS GJ et al.: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet (1997) 350(9093):1729-1733.
36. KIM WR, BADLEY AD, WIESNER RH et al.: The economic impact of cytomegalovirus infection after liver transplantation. Transplantation (2000) 69(3):357-361.
37. VIVARELLI M, DE RUVO N, LAZZAROTTO T et al.: Abstension from treatment of low-level pp65 cytomegalovirus antigenemia after liver transplantation: a prospective study. Transplantation (2000) 70(8):1183-1187.
38. BRENNAN DC, GARLOCK KA, LIPPMANN BJ et al.: Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients. Transplant. Proc. (1997) 29(1-2):809-811.
39. FALAGAS ME, ARBO M, RUTHAZER R et al.: Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation (1997) 63:1595-1601.
40. PAYA CP, PESCOVITZ MH, BLUMBERG E et al.: Efficacy and safety of once-daily oral valganciclovir versus oral gancidovir three times daily for the prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. (2004) 4:611-620.
41. PESCOVITZ MD, RABKIN J, MERION RM et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. (2000) 44:2811-2815.
42. SUGAWARA M, HUANG W, FEI YJ, LEIBACH FH, GANAPATHY V, GANAPATHY ME: Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. (2000) 89(6):781-789.
43. BALDANTI F, SARASINI A, SILINI E et al.: Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand. J. Inject. Dis. (1995) 99(Suppl.):103-104.
44. BOIVIN G, ERICE A, CRANE DD et al.: Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J. Infect. Dis. (1993) 168:332-335.
45. BROWN F, BANKEN L, SAYWELL K, ARUM I: Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Pharmacokinet. (1999) 37(2):167-176.
46. JUNG D, DORR A: Single-dose pharmacokinetics of valgancidovir in HIV- and CMV-seropositive subjects. J. Clin. Pharmacol. (1999) 39(8):800-804.
47. JUNG D, GRIFFY K, WONG R et al.: Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients. J. Clin. Pharmacol. (1998) 38:1122-1128.
48. Roche Pharmaceuticals Corp.: Valcyte® (valganciclovir) package insert. Roche Pharmaceuticals Corp., Nutley, NJ, USA (2003).
49. MARTIN DF, SIERRA-MADERO J, WALMSLEY S et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. (2002) 346(15):1119-1126.
50. LALEZARI J, LINDLEY J, WALMSLEY S et al.: A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. (2002) 30(4):392-400.
51. BOIVIN G, GOYETTE N, GILBERT C et al.: Absence of cytomegalovirus-resistance mutations after valgancidovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. (2004) 189(9):1615-1618.
52. CLARK BS, CHANG IF, KARPEN SJ et al.: Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation (2004) 77(9):1480.
53. BURRI M, WILTSHIRE H, KAHLERT C, WOUTERS G, RUDIN C: Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr. Infect. Dis. J. (2004) 23(3):263-266.